Bacteria in cancer therapy: beyond immunostimulation

Abstract

Currently, conventional therapies in cancer are improving; chemotherapy, radiotherapy and surgery have increased survival significantly. New therapies have arisen with the same goal; immunotherapy has appeared as a promising option in the fight against cancer stimulating the immune system by inducing innate and adaptive responses. These responses include release of pro-inflammatory cytokines, making the immune system capable to eliminate or protect against multiple tumors. Nowadays, many of these therapies are being used in clinical settings, such as checkpoint inhibitors, monoclonal anti cytotoxic T-Lymphocyte associated protein 4 (CTL-4) and programmed death protein 1 (PD1), with inspiring results; however, they may decrease immunotolerance, limiting their use. At the same time, chemotherapy works by passive transport across the cell membrane, limiting its capacity to penetrate in tumor cells. For these reasons, bacteria employment represents one of the best candidates for cancer treatment. They can surpass these barriers with their selective colonization which also has an oncolytic effect by increasing proliferation and immunostimulation in the tumor environment. Attenuated strains, such as Mycobacterium bovis, Clostridium, Salmonella typhimirium and Listeria monocytogenes have been studied showing promising results in experimental models. However, their application in clinical trials has shown the need to maximize their therapeutic effect. Genetic engineering and synthetic biology are necessary to prove the scope that this novel approach has against cancer due to implications of cancer therapy and public health.

Keywords

Bacterium / cancer / selective colonization / salmonella / clostridium / listeria

References

[1] Ferlay J,Dikshit R,Mathers C,Parkin DM,Bray F.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012..Int J Cancer2015;136:E359-86

[2] Ministery of Health. Bolivarian Republic of Venezuela. Anuary of Mortality 2013. Available from: http://www.ovsalud.org/descargas/publicaciones/documentos-oficiales/Anuario-Mortalidad-2013.pdf [Last accessed on 19 Jan 2018].

[3] Hainaut P.Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy..Curr Opin Oncol2013;25:50-1

[4] Burrell R,Bartek J.The causes and consequences of genetic heterogeneity in cancer evolution..Nature2013;501:338-45

[5] Fisher R,Swanton C.Cancer heterogeneity: implications for targeted therapeutics..Br J Cancer2013;108:479-85 PMCID:PMC3593543

[6] Spratt D,Yamada J,Cox B.Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer..Int J Radiat Oncol Biol Phys2013;85:686-92 PMCID:PMC5705018

[7] Senn H.Gallen consensus 2013: optimizing and personalizing primary curative therapy of breast cancer worldwide..Breast Care2013;8:101 PMCID:PMC3683954

[8] Khawar I,Kuh H.Improving drug delivery to solid tumors: Priming the tumor microenvironment..J Control Release2015;201:78-89

[9] Nagarsheth N,Zou W.Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy..Nat Rev Immunol2017;17:559-72 PMCID:PMC5731833

[10] Larkin J,Gonzalez R,Cowey C,Schadendorf D,Smylie M,Ferrucci PF,Wagstaff J,Haanen JB,Marquez-Rodas I,Ascierto PA,Callahan MK,Grossmann K,Dreno B,Yang A,Horak C,Wolchok JD.Combined nivolumab and ipilimumab or monotherapy in untreated melanoma..N Engl J Med2015;373:23-34 PMCID:PMC5698905

[11] Wolchok J,Gonzalez R,Grob J,Lao C,Schadendorf D,Smylie M,Hill A,Haanen J,Bechter O,Marquez-Rodas I,McArthur G,Ascierto P,Cebon J,Postow M,Walker D,Bhore R,Larkin J.Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma..N Engl J Med2017;377:345-56

[12] Babjuk M,Burger M,Cohen D,Hernández V,Palou J,van Rhijn BWG,Soukup V,Zigeuner R.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016..Eur Urol2017;71:447-61

[13] Roberts N,Janku F,Bai R,Rusk AW,Miller M,Khanna KV,Benjamin RS,Szvalb AD,Roy-Chowdhuri S,Qiao Y,McDaniel J,Sahora A,Phillips B,Klein MK,Diaz LAJr,Papadopoulos N,Vogelstein B,Huso DL,Saha S.Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses..Sci Transl Med2014;6:249ra111 PMCID:PMC4399712

[14] Toneri M,Zhang Y,Yano S,Bouvet M,Hoffman RM.Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cáncer experimental bone metástasis in mouse models..Oncotarget2015;6:31335-43 PMCID:PMC4741609

[15] Laurence M.Attenuated listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy..Front Cell Infect Microbiol2014;4:51

[16] Gatenby R.Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer..Biochim Biophys Acta2017;1867:162-6

[17] Zheng S,Teschendorff A.Epigenetic drift, epigenetic clocks and cancer risk..Epigenomics2016;8:705-19

[18] Grasso Frisan T.Bacterial genotoxins: merging the DNA damage response into infection biology..Biomolecules2015;5:1762-82 PMCID:PMC4598774

[19] Hanahan D.The hallmarks of cancer..Cell2000;100:57-70

[20] Behrens A,Rudolph K.Impact of genomic damage and ageing on stem cell function..Nat Cell Biol2014;16:201-7 PMCID:PMC4214082

[21] Charni M,Molchadsky A.p53 on the crossroad between regeneration and cancer..Cell Death Differ2016;24:8-14 PMCID:PMC5260496

[22] Xu JH,Shen GD.Tumor suppressor genesand their underlying interactions in paclitaxel resistance in cancer therapy..Cancer Cell Int2016;16:13 PMCID:PMC4761208

[23] Shalapour S.Immunity, inflammation, and cancer: an eternal fight between good and evil..J Clin Invest2015;125:3347-55 PMCID:PMC4588298

[24] Garg A,Agostinis P.Cancer immunogenicity, danger signals, and DAMPs: what, when, and how?.Biofactors2013;39:355-67

[25] Pritchard A,Neller M,Schmidt C.Exploration of peptides bound to MHC class I molecules in melanoma..Pigment Cell Melanoma Res2015;28:281-94

[26] Galon J,Bedognetti D.The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures..Immunity2013;39:11-26

[27] Romee R,Fehniger T.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer..Scientifica (Cairo)2014;2014:205796

[28] Gajewski T,Fu Y.Innate and adaptive immune cells in the tumor microenvironment..Nat Immunol2013;14:1014-22 PMCID:PMC4118725

[29] Payne K,Manjili M.Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy..Future Oncol2014;10:1779-94

[30] Gajewski TF,Fu YX.Innate and adaptive immune cells in the tumor microenvironment..Nat Immunol2013;14:1014-22 PMCID:PMC4118725

[31] Jandus C,Chijioke O,Dahlhaus M,Schneider C,Hunger RE,Simon HU,Münz C.Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance..J Clin Invest2014;124:1810-20 PMCID:PMC3973073

[32] Morvan M.NK cells and cancer: you can teach innate cells new tricks..Nat Rev Cancer2015;16:7-19

[33] Crouse J,Lang P.NK cells regulating T cell responses: mechanisms and outcome..Trends Immunol2015;36:49-58

[34] D'Eliseo D,Velotti F.Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells..Cell Stress Chaperones2013;18:801-8 PMCID:PMC3789874

[35] Deauvieau F,Doffin A,Fonteneau J,Durand I,Marvel J,Walzer T,Perrot I,Caux C.Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells..Int J Cancer2014;136:1085-94

[36] Ferlazzo G.Dendritic cell editing by natural killer cells..Crit Rev Oncog2014;19:67-75

[37] Messina J,Eschrich S,Berglund A,Schell MJ,Weber JS.12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy?.Sci Rep2012;2:765 PMCID:PMC3479449

[38] Wilk E,Buyny S,Jacobs R.New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles..Immunobiology2008;213:271-83

[39] Della Chiesa M,Sivori S,Pesce S.Human NK cell response to pathogens..Semin Immunol2014;26:152-60

[40] Slezak S,Wang E,Marincola F.Analysis of vaccine-induced T cells in humans with cancer..Adv Exp Med Biol2010;684:178-88 PMCID:PMC5545805

[41] Bhatia A.Cancer stem cells and tumor immunoediting: putting two and two together..Expert Rev Clin Immunol2016;12:605-7

[42] Calì B,Viola A.Tuning cancer fate: the unremitting role of host immunity..Open Biol2017;7:170006 PMCID:PMC5413907

[43] Mittal D,Schreiber R.New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape..Curr Opin Immunol2014;27:16-25 PMCID:PMC4388310

[44] Wu X,Huang B,Wang H,Xue Z,Da Y,Yao Z.Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma..Cancer Lett2013;340:124-33

[45] Teng M,Fridman W.From mice to humans: developments in cancer immunoediting..J Clin Invest2015;125:3338-46 PMCID:PMC4588291

[46] Spranger S,Horton B,Newton R.Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment..J Immunother Cancer2014;2:3 PMCID:PMC4019906

[47] Postow M,Wolchok J.Immune checkpoint blockade in cancer therapy..J Clin Oncol2015;33:1974-82 PMCID:PMC4980573

[48] Vesely M.Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy..Ann N Y Acad Sci2013;1284:1-5 PMCID:PMC3648872

[49] Sakamoto C,Inoue H,Ogawa Y,Miyamoto S,Yamada K,Tani K.Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity..Cancer Gene Ther2017;24:165-74

[50] West H.Immune Checkpoint Inhibitors..JAMA Oncol2015;1:115

[51] Vedham V,Starks V.Multiple infections and cancer: implications in epidemiology..Technol Cancer Res Treat2014;13:177-94

[52] Khan S,Khan A,Alshamsan A.Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer..PLoS One2016;11:e0148530 PMCID:PMC4752481

[53] Crowe S.Helicobacter infection, chronic inflammation, and the development of malignancy..Curr Opin Gastroenterol2005;21:32-8

[54] Krishnan S.Streptococcus bovisinfection and colorectal neoplasia: a meta-analysis..Colorectal Dis2014;16:672-80

[55] Hardbower D,Chaturvedi R.Chronic inflammation and oxidative stress..Gut Microbes2013;4:475-81 PMCID:PMC3928159

[56] Manda G,Comanescu M,Debelec Butuner B.The redox biology network in cancer pathophysiology and therapeutics..Redox Biol2015;5:347-57 PMCID:PMC4501561

[57] Kidane D,Czochor J,Glazer PM,Sweasy JB.Interplay between DNA repair and inflammation, and the link to cancer..Crit Rev Biochem Mol Biol2014;49:116-39 PMCID:PMC4300235

[58] Hoesel B.The complexity of NF-κB signaling in inflammation and cancer..Mol Cancer2013;12:86 PMCID:PMC3750319

[59] Elinav E,Thaiss C,Jin C.Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms..Nat Rev Cancer2013;13:759-71

[60] Rinkenbaugh A.The NF-κB pathway and cancer stem cells..Cells2016;5:16 PMCID:PMC4931665

[61] Van T,Straub B,Papadopoulou N.Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis..J Clin Invest2017;127:2662-77 PMCID:PMC5490752

[62] Gambhir S,Hollis M,Vyas A.Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies..World J Gastroenterol2015;21:3174-83 PMCID:PMC4363746

[63] Pawlowski A,Sköld M,Källenius G.Tuberculosis and HIV co-Infection..PLoS Pathog2012;8:e1002464 PMCID:PMC3280977

[64] Scanu T,Bakker J,Wu L,Broeks A,Kumar M,Song JY,te Riele H,Nath G.Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma..Cell Host Microbe2015;17:763-74

[65] Zhang Y,Gan R,Xu D.Impacts of gut bacteria on human health and diseases..Int J Mol Sci2015;16:7493-519 PMCID:PMC4425030

[66] Bernardes N,Fialho A.Engineering of bacterial strains and their products for cancer therapy..Appl Microbiol Biotechnol2013;97:5189-99

[67] Nauts H,Coley B.The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research..Cancer Res1946;6:205-16

[68] Coley W.End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of erysipelas and bacillus prodigiosus, alonis or combined with radiation..Ann Surg1928;88:641 PMCID:PMC1398606

[69] Coley W.Treatment of inoperable malignant tumors with the toxines of erysipelas and the bacillus prodigiosus..Am J Med Sci1894;108:50-66

[70] Coley W.The treatment of malignat tumors by repeated inoculations of erysipelas..Am J Med Sci1893;105:487-510

[71] Coley W.The mixed toxins of erysipelas and bacillus prodigiosus in the treatment of sarcoma..JAMA1900;XXXIV:906-8

[72] Nauts HC.The beneficial effects of bacterial infections on host resistance to cancer end results in 449 cases: a study and abstracts of reports in the world medical literature (1775-1980) and personal communications..Cancer Research Inst1980;24:212-6

[73] Sell S.Cancer immunotherapy: breakthrough or "deja vu, all over again"?.Tumor Biol2017;39:1010428317707764

[74] Kienle G.Fever in cancer treatment: Coley's therapy and epidemiologic observations..Glob Adv Health Med2012;1:92-100 PMCID:PMC3833486

[75] Rosenberg S.IL-2: the first effective immunotherapy for human cancer..J Immunol2014;192:5451-8

[76] Le H,Tsung K.Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12..J Immunol2001;167:6765-72

[77] Kucerova P.Spontaneous regression of tumour and the role of microbial infection-possibilities for cancer treatment..Anticancer Drugs2016;27:269-77 PMCID:PMC4777220

[78] Nallar S,Kalvakolanu D.Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges..Cytokine2017;89:160-72

[79] Chorobik P,Ossysek K.Salmonella and cancer: from pathogens to therapeutics..Acta Biochim Pol2013;60:285-97

[80] Balk R.Systemic inflammatory response syndrome (SIRS)..Virulence2013;5:20-6 PMCID:PMC3916374

[81] Brown K,Lewis S,Treacher D.Targeting cytokines as a treatment for patients with sepsis: a lost cause or a strategy still worthy of pursuit?.Int Immunopharmacol2016;36:291-9

[82] Dang LH,Huso DL,Vogelstein B.Combination bacteriolytic therapy for the treatment of experimental tumors..Proc Natl Acad Sci U S A2001;98:15155-60 PMCID:PMC64999

[83] Gujrati V,Kim S,Choy H,Jon S.Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy..ACS Nano2014;8:1525-37

[84] Piñero-Lambea C,Fernández-Periáñez R,Álvarez-Vallina L.Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins..ACS Synth Biol2015;4:463-73 PMCID:PMC4410913

[85] Lin I,Smooker P.Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery..Vaccines2015;3:940-72 PMCID:PMC4693226

[86] Kasinskas R.Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis..Cancer Res2007;67:3201-9

[87] Loeffler M,Krajewska M.Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth..Cancer Immunol Immunother2008;58:769-75

[88] Sahari A,Scharf B.Directed transport of bacteria-based drug delivery vehicles: bacterial chemotaxis dominates particle shape..Biomed Microdevices2014;16:717-25

[89] Zhou S.Synthetic biology: bacteria synchronized for drug delivery..Nature2016;536:33-4

[90] Alphandéry E.Applications of magnetosomes synthesized by magnetotactic bacteria in medicine..Front Bioeng Biotechnol2014;2:5 PMCID:PMC4126476

[91] Pyne M,Moo-Young M,Chou C.Technical guide for genetic advancement of underdeveloped and intractable Clostridium..Biotechnol Adv2014;32:623-41

[92] Nallar S,Kalvakolanu D.Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges..Cytokine2017;89:160-72

[93] Claesen J.Synthetic microbes as drug delivery systems..ACS Synth Biol2015;4:358-64 PMCID:PMC4410909

[94] Abil Z,Zhao H.Synthetic biology for therapeutic applications..Mol Pharm2014;12:322-31 PMCID:PMC4319687

[95] Allen E,Warren CM,Li L,Hanahan D.Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling..Cell Rep2016;15:1144-60 PMCID:PMC4872464

[96] Green D,Kroemer G.Metabolic control of cell death..Science2014;345:1250256 PMCID:PMC4219413

[97] Phillips R.Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs..Cancer Chemother Pharmacol2016;77:441-57 PMCID:PMC4767869

[98] Hunter F,Wilson W.Hypoxia-activated prodrugs: paths forward in the era of personalised medicine..Br J Cancer2016;114:1071-7 PMCID:PMC4865974

[99] Rhim T,Lee M.Hypoxia as a target for tissue specific gene therapy..J Control Release2013;172:484-94

[100] Dhani N,Hedley D.The clinical significance of hypoxia in human cancers..Semin Nucl Med2015;45:110-21

[101] Heap J,Ehsaan M,Dubois L,Van Mellaert L,Kuehne SA,Minton NP.Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo..Oncotarget2014;5:1761-9 PMCID:PMC4039107

[102] Hammerich L.Immunomodulation within a single tumor site to induce systemic antitumor immunity: in situ vaccination for cancer..In: Rennert P, editor. Novel Immunotherapeutic Approaches to the Treatment of Cancer.2016;ChamSpringer129-62

[103] Park D,Cho S,Lee Y,Park BJ,Park JO.Motility analysis of bacteria-based microrobot (bacteriobot) using chemical gradient microchamber..Biotechnol Bioeng2014;111:134-43

[104] Yu B,Zhang BZ,Peng X,Qu JL.Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model..Oncol Lett2015;10:1069-74 PMCID:PMC4509430

[105] Thornlow D,Gigas J,Forbes N.Persistent enhancement of bacterial motility increases tumor penetration..Biotechnol Bioeng2015;112:2397-405 PMCID:PMC4586311

[106] Pylaeva E,Jablonska J.The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils..Front Immunol2016;7:629 PMCID:PMC5174087

[107] Hiroshima Y,Zhang Y,Maawy A,Mii S,Yamamoto M,Yano S,Mori R,Chishima T,Ichikawa Y,Endo I.Tumor-targeting salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice..PLoS One2015;10:e0134324 PMCID:PMC4523197

[108] Matsumoto Y,Zhang Y,Yano S,Yamamoto M,Bouvet M,Hoffman RM.Efficacy of tumor-targetingsalmonella typhimuriumA1-R on nude mouse models of metastatic and disseminated human ovarian cancer..J Cell Biochem2014;115:1996-2003

[109] Zoaby N,Badarneh S,Leshansky A,Schroeder A.Autonomous bacterial nanoswimmers target cancer..J Control Release2017;257:68-75

[110] Toso J.Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma..J Clin Oncol2002;20:142-52 PMCID:PMC2064865

[111] Zhang Y,Zhang N,Zhao M.Tumor-targeting Salmonella typhimurium A1-R arrests growth of breast-cancer brain metastasis..Oncotarget2014;6:2615-22 PMCID:PMC4413605

[112] Alimoradi H,Gamble AB,Greish K.Hypoxia responsive drug delivery systems in tumor therapy..Curr Pharm Des2016;22:2808-20

[113] Loeffler M,Krajewska M.Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth..Proc Natl Acad Sci U S A2007;104:12879-83 PMCID:PMC1937560

[114] Loeffler M,Krajewska M.IL-18-producing Salmonella inhibit tumor growth..Cancer Gene Ther2008;15:787-94 PMCID:PMC2760299

[115] Loeffler M,Krajewska M.Inhibition of tumor growth using salmonella expressing fas ligand..J Natl Cancer Inst2008;100:1113-6 PMCID:PMC2496919

[116] Ganai S,Forbes N.Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice..Br J Cancer2009;101:1683-91 PMCID:PMC2778534

[117] Lee CH,Shiau A.Endostatin gene therapy delivered bySalmonella choleraesuis in murine tumor models..J Gene Med2004;6:1382-93

[118] Lee CH,Shiau A.Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma..Int J Cancer2008;122:930-5

[119] Zhang L,Zhao L,Ji K,Wang J,Hu J,Kopecko DJ,Xu DQ.Intratumoral delivery and suppression of prostate tumor growth by attenuated salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs..Cancer Res2007;67:5859-64

[120] Niethammer AG,Becker J,Pertl U,Eliceiri BP.A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth..Nat Med2002;8:1369-75

[121] Fensterle J,Yone C,Meyer S,Goebel W,Gentschevl.Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B..Cancer Gene Ther2007;15:85-93

[122] Lemmon MJ,Fox ME,Giaccia AJ,Brown JM.Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment..Gene Ther1997;4:791-6

[123] Fox ME,Mauchline ML,Giaccia AJ,Brown JM.Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia..Gene Ther1996;3:173-8

[124] Zhang YL,Chang ZS,Wang QB,Zhao W.Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity..Lett Appl Microbiol2014;59:580-6

[125] Groot A,Wall E,Theys J.Functional antibodies produced by oncolytic clostridia..Biochem Biophys Res Commun2007;364:985-9

[126] Gunn GR,Peters C,Wu TC.Two listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16..J Immunol2001;167:6471-9

[127] Shahabi V,Maciag P,Wallecha A.Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human..Cancer Gene Ther2010;18:53-62

[128] Kim S,Gonzalez D,Paterson Y.Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases..B J Cancer2008;99:741-9 PMCID:PMC2528142

[129] Maciag PC,Pan ZK,Paterson Y.Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature..Cancer Res2008;68:8066-75 PMCID:PMC3004011

[130] Zu C.Tumor-colonizing bacteria: a potential tumor targeting therapy..Crit Rev Microbiol2013;40:225-35

[131] Quispe-Tintaya W,Jahangir A,Casadevall A,Gravekamp C.Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer..Proc Natl Acad Sci U S A2013;110:8668-73 PMCID:PMC3666740

[132] Hosseinidoust Z,Yasa O,Singh A.Bioengineered and biohybrid bacteria-based systems for drug delivery..Adv Drug Deliv Rev2016;106:27-44

[133] Fu W,Han X,Ren D.Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models..J Gene Med2008;10:690-701

[134] Cicchelero L,Devriendt B,Sanders N.Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?.Onco Immunology2015;4:e1048413 PMCID:PMC4635695

[135] Lin IY,Smooker PM.Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery..Vaccines (Basel)2015;3:940-72 PMCID:PMC4693226

[136] Inoue H.Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments..Cell Death Differ2013;21:39-49 PMCID:PMC3857623

[137] Tsuchiya K,Fang R,Sakai S,Chen X,Qu H,Kawamura I.The adaptor ASC exacerbates lethal Listeria monocytogenes infection by mediating IL-18 production in an inflammasome-dependent and -independent manner..Eur J Immunol2014;44:3696-707

[138] Srivastava S,Feng H,Lewis D,Whitacre M,Chen YJ,Jonak ZL,Robertson MJ.Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin..Cancer Immunol Immunother2013;62:1073-82 PMCID:PMC3707624

[139] Cao H,Zhang C,Jiang L,Huang X.MDA7 combined with targeted attenuated Salmonella vector SL7207/pBud-VP3 inhibited growth of gastric cancer cells..Biomed Pharmacother2016;83:809-15

[140] Farooqi A.TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology..Appl Microbiol Biotechnol2013;97:8849-57

[141] Zheng X,Shu M,Zhou Y,Zhu W,Li S,Yan G,Hu J.Cholera toxin, a typical protein kinase A activator, induces G1 phase growth arrest in human bladder transitional cell carcinoma cells via inhibiting the c-Raf/MEK/ERK signaling pathway..Mol Med Rep2014;9:1773-9

[142] Zhao Q,Liu K,Yang G,Zhu L,Yan Z,Qian S.Microwave ablation combined with attenuated Salmonella typhimurium for treating hepatocellular carcinoma in a rat model..Oncotarget2017;8:47655-64

[143] Morgan RA,Abate-Daga D,Robbins PF,Dudley ME,Yang JC,Phan GQ,Kammula US,Hessman CJ,Restifo NP,Alimchandani M,Nath A,Bielekova B,Akula N,Wilde S,Schendel DJ,Rosenberg SA..Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother2013;36:133-51 PMCID:PMC3581823

[144] Jiang SN,Nam TK,Kim HS,Choy HE,Min JJ.Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy..Mol Ther2010;18:635-42 PMCID:PMC2839435

[145] Keates AC,Xiang S.TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery..Biotechnol Genet Eng Rev2008;25:113-28

[146] Yang N,Lü YZ,Ren DM.Attenuated Salmonella typhimurium carrying shRNA-expressing vectors elicit RNA interference in murine bladder tumors..Acta Pharmacol Sin2011;32:368-74 PMCID:PMC4002778

[147] Tian Y,Jia H,Sun Y,Zhao T,Meng Y,Kopecko DJ,Zhang L.Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC..Cancer Gene Ther2012;19:393-401 PMCID:PMC3891655

[148] Yu YA,Szalay AA.Real-time imaging of tumors using replication-competent light-emitting microorganisms..Methods Mol Biol2012;872:159-75

[149] Brader P,Riedl CC,Cai S,Ghani ER,Szalay AA,Blasberg R.Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging..Clin Cancer Res2008;14:2295-302

[150] Viczián A.Luciferase and green fluorescent protein reporter genes as tools to determine protein abundance and intracellular dynamics..Methods Mol Biol2010;655:293-312

[151] Voisey CR.Elimination of internal restriction enzyme sites from a bacterial luminescence (luxCDABE) operon..Biotechniques1998;24:56-8

[152] Sörensen M,Kaiser T,Aebischer T.Rapidly maturing red fluorescent protein variants with strongly enhanced brightness in bacteria..FEBS Lett2003;552:110-4

[153] Yu YA,Szalay AA.Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria..Biotechnol Bioeng2008;100:567-78

[154] Araujo AC,Silva KT,Lins U.Magnetotactic bacteria as potential sources of bioproducts..Mar Drugs2015;13:389-430 PMCID:PMC4306944

[155] Nakamura C,Sode K.An iron-regulated gene, magA, encoding an iron transport protein of magnetospirillum sp. strain AMB-1..J Biol Chem1995;270:28392-6

[156] Mannucci S,Conti G,Lascialfari A,Benati D,Betterle N,Marzola P.Magnetic nanoparticles from magnetospirillum gryphiswaldense increase the efficacy of thermotherapy in a model of colon carcinoma..PLoS One2014;9:e108959 PMCID:PMC4188607

[157] Want CZ,Eisenstark A.Straings, mechanism and perspective; Salmonella-based cancer therapy..Int J Microbiol2016;2016:5678702

[158] Danino T,Kwong G,Li H,Hasty J.Programmable probiotics for detection of cancer in urine..Sci Transl Med2015;7:289ra84 PMCID:PMC4511399

[159] Mangtani P,Ariti C,Pimpin L,Rodrigues LC,Lipman M,Sterne JA.Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials..Clin Infect Dis2013;58:470-80

[160] Kassouf W,Kulkarni GS,Zlotta A,So A,Rendon R,Siemens DR,Black P.CUA guidelines on the management of non-muscle invasive bladder cancer..Can Urol Assoc J2015;9:690 PMCID:PMC4662433

[161] Sylvester RJ,Oosterlinck W,Bouffioux C,Newling DW.Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using eortc risk tables: a combined analysis of 2596 patients from seven EORTC trials..Eur Urol2006;49:466-77

[162] Sylvester RJ,Kirkels WJ,Calais Da Silva F,Prescott S,van de Beek C,de Reijke TM.Long-term efficacy results of eortc genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus calmette-guérin, and bacillus calmette-guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder..Eur Urol2010;57:766-73 PMCID:PMC2889174

[163] Babjuk M,Zigeuner R,van Rhijn BW,Sylvester RJ,Böhle A,Rouprêt M.EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013..Eur Urol2013;64:639-53

[164] Brausi M,Sylvester R,van de Beek C,Gontero P,Marreaud S,Oosterlinck W.Side Effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG..Eur Urol2014;65:69-76

[165] Redelman-Sidi G,Bochner B.The mechanism of action of BCG therapy for bladder cancer-a current perspective..Nat Rev Urol2014;11:153-62

[166] Kawai K,Joraku A,Akaza H.Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine..Cancer Sci2013;104:22-7

[167] Pandith AA,Azad NA,Wani MS.Association of chemokine and chemokine receptor gene polymorphis (MCP1 A-2518G and CCR2-V64I) with urinary bladder cancer: a study in kashmiri population..Am J Mol Cell Biol2013;2:1-13

[168] Fuge O,Allchorne P.Immunotherapy for bladder cancer..Res Rep Urol2015;7:65-79 PMCID:PMC4427258

[169] Bunimovich-Mendrazitsky S,Kronik N.Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model..Math Med Biol2016;33:159-88

[170] Iqbal NT.Non-specific immunity of BCG vaccine: a perspective of BCG immunotherapy..Trials Vaccinol2014;3:143-9

[171] Kates M,Sopko NA,Kochel CM,Netto GJ,Hahn NM,Baras AS,Bivalacqua TJ.Intravesical BCG Induces CD4 + T-cell expansion in an immune competent model of bladder cancer..Cancer Immunol Res2017;5:594-603 PMCID:PMC5536898

[172] Gandhi NM,Lamm DL.Bacillus Calmette-Guérin immunotherapy for genitourinary cancer..BJU Int2013;112:288-97

[173] Amarante-Mendes GP.Therapeutic applications of TRAIL receptor agonists in cancer and beyond..Pharmacol Ther2015;155:117-31 PMCID:PMC4955572

[174] Liu X,Patel P,Foster MC,James ND.Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin..Future Oncol2014;10:1443-56

[175] Nemunaitis J,Senzer N,Cramm J,Cavagnolo R,Clairmont C.Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients..Cancer Gene Ther2003;10:737-44

[176] Schmitz-Winnenthal FH,Niethammer A,Lubenau H,Breiner KM,Weitz J,Buechler MW,Klaiber U,Leowardi C,Sisic L,Koc R,Knebel P,Ge Y,Stamova S,Haefeli WE,Beckhove P.Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial..Onco Immunol2015;4:e1001217 PMCID:PMC4485742

[177] Le DT,Nir-Paz RG,Mathur S,Sterman DH,Lutz E,Giedlin M,Sugar EA,Cox AL,Murphy AL,Dubensky TWJr,Jaffee EM.A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction..Clin Cancer Res2011;18:858-68 PMCID:PMC3289408

[178] Le DT,Picozzi V,Crocenzi T,Morse M,Cohen D,Onners B,Laheru DA,Solt S,Skoble J,Grous J,Brockstedt DG.Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer..J Clin Oncol2015;33:1325-33 PMCID:PMC4397277

[179] Pollheimer M,Lindtner R,Schlemmer A,Langner C.Tumor necrosis is a new promising prognostic factor in colorectal cancer..Hum Pathol2010;41:1749-57

[180] Ladstein RG,Straume O.Tumor necrosis is a prognostic factor in thick cutaneous melanoma..Am J Surg Pathol2012;36:1477-82

[181] Swinson D,Richardson D,Edwards J.Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables..Lung Cancer2002;37:235-40

[182] Staedtke V,Sun W,Kibler KK,Gallia GL,Vogelstein B,Riggins GJ.Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats..Oncotarget2015;6:5536-46 PMCID:PMC4467385

[183] Krick EL,Rankin SC,Kobrin B,Kinzler KW,Zhou S.Evaluation of Clostridium novyi -NT spores in dogs with naturally occurring tumors..Am J Vet Res2012;73:112-8 PMCID:PMC4596235

[184] Kubiak A.The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy..Res Microbiol2015;166:244-54

[185] Maciag P,Rothman J.The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix..Vaccine2009;27:3975-83

[186] Theys J,Dubois L,Vaughan T,Landuyt W,Burke PJ,Wouters BG,Lambin P.Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo..Br J Cancer2006;95:1212-9 PMCID:PMC2360559

[187] Fabricius EM,Schau HP,Benedix A.Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration..Res Microbiol1993;144:741-53

[188] Nuyts S,Theys J,Bosmans E,Lambin P.Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation..Gene Ther2001;8:1197-1201

[189] Barbé S,Theys J,Lammertyn E,Anné J.Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment..FEMS Microbiol Lett2005;246:67-73

[190] Bermudes D,Ittensohn M,Platt J,Amoss M,Carmichael E,Fischer J,Luo X,Zheng L,Pawelek JM.Lipid a mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo..Nat Biotechnol1999;17:37-41

[191] Clairmont C,Pike J,Low KB,Bermudes D,Margitich D,Li Z,King I.Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium..J Infect Dis2000;181:1996-2002

[192] Forbes N.Engineering the perfect (bacterial) cancer therapy..Nat Rev Cancer2010;10:785-94 PMCID:PMC3756932

[193] Aghi M,Breakefield X.Prodrug activation enzymes in cancer gene therapy..J Gene Med2000;2:148-64

[194] Nagakura C,Zhao M,Yamamoto N,Tomita K,Hoffman RM.Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice..Anticancer Res2009;29:1873-8

[195] Hiroshima Y,Zhang Y,Hassanein M,Miwa S,Momiyama M,Chishima T,Bouvet M,Hoffman RM.Comparison of efficacy of Salmonella typhimuriumA1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells..Cell Cycle2013;12:2774-80 PMCID:PMC3899191

[196] Momiyama M,Kimura H,Chishima T,Endo I.Inhibition and eradication of human glioma with tumor-targetingSalmonella typhimuriumin an orthotopic nude-mouse model..Cell Cycle2012;11:628-32 PMCID:PMC3315098

[197] Murakami T,Zhao M,Chishima T,Bouvet M,Hoffman RM.Therapeutic efficacy of tumor-targeting Salmonella typhimurium A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models..Oncotarget2015;6:31368-77

[198] Matsumoto Y,Zhang Y,Yano S,Yamamoto M,Bouvet M,Hoffman RM.Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer..J Cell Biochem2014;115:1996-2003

[199] Zhang Y,Zhao M.Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice..Oncotarget2015;6:14625-31

[200] Yano S,Miwa S,Hiroshima Y,Yamamoto M,Kishimoto H,Zhao M,Fujiwara T.Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness..Cell Cycle2014;13:2110-9 PMCID:PMC4111702

[201] Yano S,Zhao M,Miwa S,Kishimoto H,Bouvet M,Hoffman RM.Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycles as visualized by FUCCI imaging and become sensitive to chemotherapy..Cell Cycle2014;13:2958-3963 PMCID:PMC4615054

[202] Jia H,Zhao T,Hu J,Guo B,Zhao X,Xu DQ.Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma..Cancer Immunol Immunother2012;61:1977-87

[203] Park SY.Signal-specific temporal response by the SalmonellaPhoP/PhoQ regulatory system..Mol Microbiol2013;91:135-44 PMCID:PMC3890429

[204] Hohmann EL,Killeen KP.PhoP/PhoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers..J Infect Dis1996;173:1408-14

[205] Yu H,Jove R.STATs in cancer inflammation and immunity: a leading role for STAT3..Nat Rev Cancer2009;9:798-809 PMCID:PMC4856025

[206] Nam S,Turkson J,Cheng JQ,Hippe F,Merz KH,Jove R.Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells..Proc Natl Acad Sci U S A2005;102:5998-6003 PMCID:PMC1087919

[207] Wake MS.STAT3 the oncogene-still eluding therapy?.FEBS J2015;282:2600-11

[208] Chen Y,Jin C,Navab R,Chen XQ,Li TT,Wang XC.An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth..Tumour Biol2015;37:2395-404

[209] Xu X,Guo L,Courtney AN,Liu D,Manuel ER,Hensel M.Effective cancer vaccine platform based on attenuated Salmonella and a Type III secretion system..Cancer Res2014;74:6260-70 PMCID:PMC4216746

[210] Weiskirch LM,Paterson Y.The tumor recall response of antitumor immunity primed by a live, recombinant listeria monocytogenes vaccine comprises multiple effector mechanisms..Clin Immunol2001;98:346-57

[211] Jahangir A,Quispe-Tintaya W,Selvanesan BC.Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms..Onco Immunology2017;6:e1342025

[212] Wallecha A,Malinina I.Listeria monocytogenes (Lm)-LLO Immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment..J Immunother2013;36:468-76

[213] Pan Z,Pardoll D.Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine..Cancer Res1995;55:4776-9

[214] Wallecha A,Maciag PC,Shahabi V.Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics..Adv Appl Microbiol2009;66:1-27

[215] Birmingham CL,Kaniuk NA,Higgins DE.Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles..Nature2008;451:350-4

[216] Schnupf P,Varshavsky A.Listeriolysin O secreted by Listeria monocytogenes into the host cell cytosol is degraded by the N-end rule pathway..Infect Immun2007;75:5135-47 PMCID:PMC2168281

[217] Eitel J,Opitz B.Innate immune recognition and inflammasome activation in Listeria monocytogenes infection..Front Microbiol2011;1:149 PMCID:PMC3095400

[218] Weiskirch L.Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease..Immunol Rev1997;158:159-69

[219] Ikonomidis G,Kos FJ.Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes..J Exp Med1994;180:2209-18

[220] Mata M,Zubair A,Paterson Y.Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge..Vaccine2001;19:1435-45

[221] Singh R.Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic..Hum Vaccin2011;7:497-505

[222] Tilney LG.Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes..J Cell Biol1989;109:1597-608

[223] Theisen E.Listeria monocytogenesand the inflammasome: from cytosolic bacteriolysis to tumorimmunotherapy..Curr Top Microbiol Immunol2016;397:133-60 PMCID:PMC5027901

[224] Cory L.ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen..Hum Vaccin Immunother2014;10:3190-5 PMCID:PMC4514130

[225] Shahabi V,Wallecha A,Paterson Y.Development of a Listeria monocytogenes based vaccine against prostate cancer..Cancer Immunol Immunother2008;57:1301-3

[226] Chen Y,Li S,Jiang R,Frankel FR.Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma..Oncogene2011;31:2140-52

[227] Keenan B,Kafrouni M,Lauer P,Rucki AA,Coussens LM,Dubensky TWJr,Armstrong TD.A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice..Gastroenterology2014;146:1784-94 PMCID:PMC4035450

[228] Wood L.Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy..Front Cell Infect Microbiol2014;4:51 PMCID:PMC4026700

[229] Brockstedt D,Giedlin M,Leong M,Luckett W,Schnupf P,Castro G,Sampson-Johannes A,Stassinopoulos A,Hearst JE,Cook DN.Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity..Nat Med2005;11:853-60

[230] Li Z,Higgins DE.Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity..Infect Immun2005;73:5065-73 PMCID:PMC1201188

[231] Lauer P,Loessner M,Calendar R.Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors..J Bacteriol2002;184:4177-86 PMCID:PMC135211

[232] Angelakopoulos H,Sisul DM,Miller JF.Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation..Infect Immun2002;70:3592-3601 PMCID:PMC128066

[233] Verch T,Paterson Y.Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines..Infect Immun2004;72:6418-25 PMCID:PMC523039

[234] Sacco JJ,Harrington KJ,Powell N,Jones TM.Systemic listeriosis following vaccination with the attenuated Listeria monocytogenestherapeutic vaccine, ADXS11-001..Hum Vaccin Immunother2015;12:1085-6 PMCID:PMC4962931

[235] Correction: mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies..Cancer Immunol Res2015;3:217

[236] Hassan R,Lerner M,Postier R.Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis..Am J Clin Pathol2005;124:838-45

[237] He X,Riedel H,Yang Y,Rojanasakul Y.Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells..Mol Cancer2017;16:63 PMCID:PMC5348784

[238] Mkrtichyan M,Abu Eid R,Singh R,Khleif SN.Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy..J Immunother Cancer2013;1:15 PMCID:PMC4019896

[239] Han KJ,Park H.Anticancer and anti-inflammatory activity of probiotic lactococcus lactis NK34..J Microbiol Biotechnol2015;25:1697-701

[240] Kim JY,Kim YS,Lee HJ.Cell cycle dysregulation induced by cytoplasm of lactococcus lactis ssp. lactis in SNUC2A, a colon cancer cell line..Nutr Cancer2003;46:197-201

[241] Kim SY,Lee KW.Lactococcus lactis ssp. lactis inhibits the proliferation of SNU-1 human stomach cancer cells through induction of G0/G1 cell cycle arrest and apoptosis via p53 and p21 expression..Ann N Y Acad Sci2009;1171:270-5

[242] Maletzki C,Kreikemeyer B.Pancreatic cancer regression by intratumoral injection of live Streptococcus pyogenes in a syngeneic mouse model..Gut2008;57:483-91

[243] Yin X,Tang Z,Ren J,Tang W.Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer..Cancer Gene Ther2012;20:77-81

[244] Bhatnagar PK,Nomellini JF,Suresh MR.Anti-tumor effects of the bacterium caulobacter crescentus in murine tumor models..Cancer Biol Ther2006;5:485-91

[245] Nguyen VA,Hoang TV,Pham AT,Phan TN.Killed Bacillus subtilis spores expressing streptavidin: a novel carrier of drugs to target cancer cells..J Drug Target2013;21:528-41